Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock Has Consensus Price Target of $98.31 According to Analysts

Key Points

• Analyst sentiment is moderately bullish: Fourteen analysts give Arrowhead Pharmaceuticals a consensus “Moderate Buy” rating, with ten buys, three holds and one sell. The average 12-month price target is $98.31, above the reported share price of $65.92.
• Recent financial results were mixed: Quarterly revenue reached $75.25 million, up 171% year over year and above estimates, but adjusted loss per share of $1.36 was wider than expected. Analysts project a full-year loss of $3.62 per share.
• Institutional ownership is substantial, while insiders recently sold shares: Institutional investors own 62.61% of the company, including a newly reported $1.2 billion BlackRock stake. Two directors sold shares in August, reducing their holdings, while insider ownership stands at 3.60%.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) has been given an average recommendation of "Moderate Buy" by the fourteen ratings firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating and ten have issued a buy rating on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $98.31.

Several brokerages recently commented on ARWR. Chardan Capital reiterated a "buy" rating and set a $115.00 price target on shares of Arrowhead Pharmaceuticals in a report on Monday, August 31st. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $100.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Monday, August 31st. HC Wainwright reiterated a "buy" rating and issued a $120.00 price target on shares of Arrowhead Pharmaceuticals in a report on Tuesday, September 1st. Stifel Nicolaus started coverage on Arrowhead Pharmaceuticals in a research report on Tuesday, July 14th. They issued a "buy" rating and a $98.00 price objective on the stock. Finally, Morgan Stanley upped their price objective on Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the company an "overweight" rating in a research report on Thursday, July 23rd.

Arrowhead Pharmaceuticals Price Performance

Shares of Arrowhead Pharmaceuticals stock opened at $65.92 on Monday. The stock has a market cap of $9.29 billion, a price-to-earnings ratio of -29.30 and a beta of 1.28. The company has a debt-to-equity ratio of 1.77, a quick ratio of 5.90 and a current ratio of 5.90. The stock has a 50 day moving average price of $82.45 and a 200-day moving average price of $75.53. Arrowhead Pharmaceuticals has a one year low of $31.45 and a one year high of $95.49.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.13). The firm had revenue of $75.25 million for the quarter, compared to the consensus estimate of $44.17 million. Arrowhead Pharmaceuticals had a negative net margin of 47.79% and a negative return on equity of 60.06%. The company's revenue was up 171.0% on a year-over-year basis. During the same quarter last year, the firm earned ($1.26) EPS. Equities analysts expect that Arrowhead Pharmaceuticals will post -3.62 EPS for the current year.

Insiders Place Their Bets

In other news, Director Michael Perry sold 11,600 shares of the company's stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $87.30, for a total value of $1,012,680.00. Following the transaction, the director directly owned 111,459 shares in the company, valued at approximately $9,730,370.70. This represents a 9.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Adeoye Olukotun sold 2,000 shares of the firm's stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $86.96, for a total transaction of $173,920.00. Following the completion of the transaction, the director directly owned 31,600 shares in the company, valued at $2,747,936. This represents a 5.95% decrease in their position. The SEC filing for this sale provides additional information. 3.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. purchased a new stake in shares of Arrowhead Pharmaceuticals in the 2nd quarter worth $1,208,838,000. Geode Capital Management LLC raised its holdings in shares of Arrowhead Pharmaceuticals by 4.3% in the fourth quarter. Geode Capital Management LLC now owns 3,264,963 shares of the biotechnology company's stock valued at $216,799,000 after acquiring an additional 133,921 shares in the last quarter. Baker BROS. Advisors LP lifted its stake in Arrowhead Pharmaceuticals by 30.2% in the fourth quarter. Baker BROS. Advisors LP now owns 2,175,645 shares of the biotechnology company's stock worth $144,441,000 after acquiring an additional 504,883 shares during the period. Arrowstreet Capital Limited Partnership lifted its stake in Arrowhead Pharmaceuticals by 0.3% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 2,087,953 shares of the biotechnology company's stock worth $138,619,000 after acquiring an additional 6,264 shares during the period. Finally, Fred Alger Management LLC lifted its stake in Arrowhead Pharmaceuticals by 497.4% in the fourth quarter. Fred Alger Management LLC now owns 1,832,997 shares of the biotechnology company's stock worth $121,693,000 after acquiring an additional 1,526,164 shares during the period. Institutional investors own 62.61% of the company's stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc NASDAQ: ARWR is a biopharmaceutical company focused on developing medicines that silence disease-causing genes. The company uses RNA interference (RNAi), a biological process that reduces the production of specific proteins, to target conditions that may be difficult to treat with conventional drugs.

Arrowhead's proprietary TRiM platform is designed to deliver RNAi-based therapies to different tissues, including the liver, lungs and other organs. Its investigational pipeline has included candidates for cardiovascular and metabolic diseases, liver disorders, pulmonary conditions and inflammatory diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.